Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galandiuk, S.
Right arrow Articles by LaRocca, R. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galandiuk, S.
Right arrow Articles by LaRocca, R. V.

Annals of Surgical Oncology, Vol 3, Issue 3 270-276, Copyright © 1996 by Society of Surgical Oncology

ARTICLES

Suppository delivery of 5-fluorouracil in rectal cancer

S. Galandiuk, W. Wrightson, L. Marr, S. Myers and R. V. LaRocca
Department of Surgery, University of Louisville, Kentucky 40292, USA.

BACKGROUND: Preoperative radiotherapy with concomitant intravenous 5-fluorouracil (5-FU-i.v.) is effective in shrinking locally advanced rectal cancers and facilitating subsequent surgery. Topical 5-FU application may enhance its radiosensitizing and cytotoxic effects. Suppository and intravenous 5-FU administration were compared with respect to myelo-suppression and tissue concentrations. METHODS: Rats received 120 mg/kg 5-FU-i.v. or via suppository (5-FU-S). White blood cell count, serum albumin, alkaline phosphatase, creatinine, and aspartate aminotransferase (AST) were determined before and serially after 5-FU administration. In a separate experiment, rats received 5-FU-S or 5-FU-i.v. as already described. Portal and systemic blood, rectal, iliac lymph node, liver, and lung tissue were harvested for high-performance liquid chromatography determination of 5-FU concentrations 30 min, 1, 3, 6, and 12 h after drug administration. RESULTS: No toxicity was observed in 5-FU-S animals, whereas 63% of 5-FU-IV animals had diarrhea. Weight loss and myelosuppression occurred only in 5-FU-i.v. animals. Rectal drug concentrations were significantly higher in the 5-FU-S animals compared with 5-FU-i.v. animals, 0.5-6 h after drug administration. Blood, liver, and lung 5-FU concentrations with 5-FU-S were comparable to those with 5-FU-i.v. CONCLUSIONS: 5-FU suppositories are associated with fewer systemic side effects and higher rectal 5-FU concentrations than with 5-FU-i.v. administration.


This article has been cited by other articles:


Home page
 Arch SurgHome page
N. Han and S. Galandiuk
Induction Chemoradiation for Rectal Cancer
Arch Surg, December 1, 2006; 141(12): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. K. Kim, J. S. Min, J. K. Park, S. H. Yun, J. S. Sung, H. C. Jung, and J. K. Roh
Intravenous 5-Fluorouracil Versus Oral Doxifluridine as Preoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Prospective Randomized Trials
Jpn. J. Clin. Oncol., January 1, 2001; 31(1): 25 - 29.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Society of Surgical Oncology.